M

Mass General Brigham

Early-stage life science venture investor

Social Worker - Licensed Clinical Social Worker/Licensed Independent Clinical Social Worker, OB Ante/Post-Partum

Full-TimePosted on 9/28/2026
$68.2k - $103.2k/yr
Entry, Junior, Mid
Master's
Boston, MA, USA
In PersonOnsite at 45 Francis Street, Boston.
Medical, Clinical & VeterinaryMental & Behavioral Health

About the job

Requirements
  • A Master of Social Work (MSW) from an accredited program is required.
  • A Massachusetts Licensed Independent Clinical Social Worker (LICSW), or Licensed Clinical Social Worker (LCSW) with relevant clinical experience, is required.
  • Social Worker I requires 0–1 year of clinical experience in a medical setting and an LCSW state license.
  • Social Worker II requires 2–3 years of clinical experience in a medical setting and an LICSW state license.
  • Hires with an LCSW must obtain LICSW licensure within 12 months of eligibility to sit for the LICSW exam.
  • Clinical experience, understanding, and comfort working with patients of all ages who have complex medical and psychiatric problems, their families, and helping them understand and access resources required to support care.
  • Ability to provide rapid clinical psychosocial assessments and brief, short- or long-term treatment or management with individuals, families, couples, and groups.
  • Advanced crisis intervention, treatment, and management skills, with strong assessment and treatment skills.
  • Differential diagnosis and treatment across modalities.
  • Competence in abuse, neglect, violence, trauma, grief, loss, and bereavement.
  • Cultural sensitivity and demonstrated competency in age-specific behaviors.
  • Knowledge of specific medical and psychiatric illnesses, procedures, and treatments.
  • Excellent clinical social work assessment and crisis intervention knowledge and skills.
  • Strong understanding of psychiatric and family-system problems and ability to formulate succinct case summaries.
  • Knowledge of community agencies and resources, and ability to advocate and negotiate systems for or with patients and families.
  • Demonstrated ability to understand the social worker's role in a complex, fast-paced medical environment.
  • Demonstrated ability to consult and teach.
  • Demonstrated ability to communicate effectively orally and in writing, including interpersonal and negotiation skills needed to collaborate within a multidisciplinary team.
  • Tolerance for ambiguity, analytical skills, and computer literacy.
  • Ability to provide care appropriate to the ages of patients served in assigned areas.
  • Must be prepared to come to work or stay at work during a hospital emergency.
Responsibilities
  • Meet with ante/post-partum patients in the inpatient setting and support patients and families by connecting them with applicable resources, facilitating problem solving around social determinant of health needs, using brief therapeutic interventions when applicable, and collaborating with internal stakeholders and external agencies and organizations to ensure safe discharges and appropriate post-discharge follow-up.
  • Provide and oversee psychosocial care for selected patients and families, conduct biopsychosocial assessments, provide indicated interventions and treatment, identify high-risk psychosocial factors affecting health status, and help hospital staff understand their influence on medical care.
  • Conduct patient assessments addressing mental health and psychiatric history, emotional issues, coping style, understanding of illness, adjustment and compliance, barriers to care, cultural issues, abuse or neglect, and domestic violence.
  • Assess family relationships and systems as they relate to patient care; identify family decision makers and caregivers, understanding of illness and care trajectory, coping style, resources, and cultural issues.
  • Provide individual, group, or family counseling; caregiver and family counseling and support; advocacy for access to services and resources; and referrals to other providers as needed.
  • Develop comprehensive biopsychosocial assessments responsive to age-specific and cultural needs, and provide psychotherapy, psychosocial counseling, crisis intervention, care coordination, complementary therapies, information and referral, and safety planning.
  • Conduct mandated assessments when abuse of a child, disabled adult, or elder is suspected; conduct safety assessments when domestic violence is reported; and file reports as indicated.
  • Identify psychosocial, financial, legal, psychiatric, or substance-use factors affecting patient care management and collaborate with the team to facilitate care.
  • Communicate regularly with interdisciplinary healthcare team members about cases and emerging issues, and document timely, relevant information.
  • Coordinate family and team meetings as needed; provide psychosocial consultation on patient care planning, patient and family management, and community resources; and implement psychosocial programs based on identified needs.
  • Facilitate appropriate and efficient use of hospital and community resources.
  • Participate in formal and informal clinical case reviews, clinical supervision, educational seminars, and research projects.
  • Intervene with individuals, departments, and agencies regarding service delays that may affect care quality, length of stay, or appropriateness of admissions.
  • Review assigned caseload information, determine anticipated length of stay and psychosocial barriers, and plan care transitions and discharge with the Nurse Care Coordinator.
  • Coordinate with home care, community agencies, and facilities to ensure safe and timely patient care transitions.
  • Negotiate follow-up contact with patients, families, community agencies, or facilities to evaluate care transitions and identify service-delivery problems.
  • Coordinate communication with patients and families about the plan of care, including family meetings and warm handoffs.
  • Ensure patients and families are involved in all phases of care to the greatest extent possible and receive consistent information about care.
  • Maintain current knowledge of service-delivery needs within social, governmental, protective-services, and legal agencies.
  • Participate in departmental quality-assessment data collection and quality-assessment and improvement activities evaluating the appropriateness and effectiveness of care coordination service delivery.
  • Communicate and collaborate with the Social Work Manager and team to ensure efficient, high-quality patient care and equitable caseloads.
  • Assess patient and family learning needs, styles, and readiness; educate them based on treatment plans; and identify barriers to care, diversity issues, and learning styles.
  • Mentor, precept, and teach social workers, social work residents, students, and staff; teach in departmental and hospital seminars, workshops, and rounds as appropriate.
  • Demonstrate expert clinical social work practice and provide education and consultation to interdisciplinary healthcare providers, social work staff, and the community on psychosocial issues.
  • Support professional growth and development and contribute to an environment conducive to the professional growth of others.
  • Participate in departmental and hospital committees and may participate in social work research.
  • Complete administrative duties, including timely and appropriate medical-record documentation, daily activity reporting, use of hospital scheduling systems, and accurate reporting of hours worked.
  • Provide clinical documentation, including psychosocial assessments and progress notes, and meet billing compliance requirements when applicable.
  • Attend and participate in staff meetings and interdisciplinary meetings and rounds.
  • Adhere to and foster compliance with the National Association of Social Workers Code of Ethics and departmental and hospital clinical, quality, compliance, safety, policy, and procedural standards.
  • Meet departmental productivity standards; ambulatory, emergency department, and emergency department on-call staff are responsible for billable hours.
  • Follow applicable legal, regulatory, accreditation, and ethical practice standards; follow safe practices and hospital policies and procedures; complete required training; and bring potential non-compliance to a supervisor or appropriate hospital staff.
  • Provide clinical care in settings including the bedside, treatment areas, offices, and patients' homes.
  • Work within the department's seven-day operating schedule and flexible hours to meet the needs of patients, families, the hospital, and staff.
Desired Qualifications
  • Bilingual proficiency in English and Spanish is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

INACTIVE